Document Detail

Uric acid and hypertension.
MedLine Citation:
PMID:  16375735     Owner:  NLM     Status:  MEDLINE    
Increased levels of uric acid are associated with cardiovascular disease and the metabolic syndrome. They may predict clinical outcomes and also the onset of hypertension, though it is less clear that hyperuricaemia can be regarded as an independent risk factor given its clustering with other well-recognised factors. Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction. It is notable that the synthesis of uric acid may be associated with the generation of reactive oxygen species if the enzyme xanthine oxidorectase is converted to the oxidase, as may occur in ischaemia. It has been suggested that uric acid may play a role in the pathogenesis of early-onset hypertension but evidence for this is limited. There is also very limited data to suggest that in some circumstances lowering uric acid can lower blood pressure. In the metabolic syndrome, the presence of elevated uric acid concentrations is closely associated with raised triglyceride levels, for reasons that have not been clearly defined. It remains to be seen whether uric acid could or should be considered a specific therapeutic target in cardiovascular disease and especially in hypertension and if so what should be the optimal pharmacological approach to lowering serum urate levels.
Michael Schachter
Related Documents :
16213555 - Perfluorinated chemicals in selected residents of the american continent.
8908255 - Gender difference in the concentration of the antioxidant uric acid in human nasal lavage.
15076175 - Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link.
3707135 - Uric acid protection of nucleobases from ozone-induced degradation.
11262015 - Effects of olive fruit quality and oil storage practices on the diacylglycerol content ...
23774265 - Ras and macropinocytosis: trick and treat.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  11     ISSN:  1381-6128     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-26     Completed Date:  2006-01-18     Revised Date:  2006-02-27    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  4139-43     Citation Subset:  IM    
Department of Clinical Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, St Mary's Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hypertension / etiology*
Hyperuricemia / complications*,  therapy
Insulin Resistance
Uric Acid / metabolism,  toxicity
Reg. No./Substance:
69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dietary factors and hyperuricaemia.
Next Document:  Uric acid and oxidative stress.